• Aucun résultat trouvé

This section for ANSM only EC.DM-COS@ansm.sante.fr Vigilance report : Initial report ANSM -

N/A
N/A
Protected

Academic year: 2022

Partager "This section for ANSM only EC.DM-COS@ansm.sante.fr Vigilance report : Initial report ANSM -"

Copied!
3
0
0

Texte intégral

(1)

ANSM -

Agence nationale de sécurité du médicament et des produits de santé Form 5 Clinical investigation involving a medical device or an in vitro

diagnostic medical device

Vigilance report : Initial report

Articles L. 1123-10 and R. 1123-39 to 1123- 44, R. 1123-48 and R. 1123-54 of the public health code

Suspected unexpected serious adverse effect

Serious adverse event possibly related to the procedure for implementation of the medical device To be sent

By email (preferred) to:

EC.DM-COS@ansm.sante.fr

(in the subject line, type in “VIGILANCE” and the number assigned by the ANSM (French Health Product Safety Agency) during registration of the application for marketing authorization and opinion)

By mail to:

Agence nationale de sécurité du médicament et des produits de santé (ANSM) Direction des dispositifs médicaux thérapeutiques et des cosmétiques

Essais cliniques

143-147 Boulevard Anatole France 93285 Saint-Denis cedex

By fax to: 33 01.55.87.37.17

(Send to the attention of ANSM/DMTCOS)

This section for ANSM only

Date received of the report :      /     /     

Registration number:      /     /     /ei      

ANSM - version 2 - july 2013 1/3

(2)

Clinical investigation identification

Clinical investigation registration number from the ANSM:      

Code number of the Clinical investigation assigned by the sponsor, version and date:      

Full title of the biomedical research:      

Code number identifying the Clinical investigation participant:      

Patient initials: Surname initial:       First name initial:      

Gender: F: M: Date of birth:      /     /      and/or Age:      years Medical device used:

Common device name (for example: arterial stent):      

Trade name (if CE mark):      

Model:       Version (including software):      

Serial no.:       Batch no.:      

Reason for which the device was used in this patient:      

How the device was used:      

Starting date of this device utilization :      /     /      Termination date of this device utilization :      /     /      Was there “unblinding”? yes no N/A

If yes, results:      

Other treatments:

Concomitant drug therapy and non-drug treatments (dosage, date treatment began, etc.):

______________________________________________________________________________

Information about the suspicion of serious adverse effects or events:

Complete description including signs and/or symptoms, organ affected, severity, and the criteria that qualifies the effect as serious; if necessary, explain the diagnosis:

     

Description of the adverse effect or event:

Date of 1st onset      /     /     

End date      /     /      or duration (specify time period):      

What were the consequences when the device was suspended and, if applicable, when the device was reintroduced:

     

Place of occurrence (research centre, hospital, day hospital, home, nursing home, etc.)      

Follow-up will be mentioned (information related to recovery and possible after-effects (sequels), additional tests and if necessary, specific treatments required and their results).

Death give the cause:      

Any additional information about a possible cause/effect relationship, especially including any information resulting from an eventual autopsy or other post-mortem tests (including the medical examiner report) when they are available:

     

Important details factors that can help in the evaluation of the case : related pathologies (can have a causal

ANSM - version 2 - july 2013 2/3

(3)

relationship with the serious adverse event - SAE), Medical and family histories; results obtained through special investigations:

     

______________________________________________________________________________

Possible Cause/Effect Relationship Imputability estimate

by the sponsor:

- to MD: certain likely possible not likely

to the procedure for implementation of the MD:

certain: likely: possible: not likely:

by the investigator (only in the case of a discrepancy between the sponsor and investigator):

- to MD: certain likely possible

not likely

to the procedure for implementation of the DM:

certain: likely: possible: not likely:

Important comments:

     

Identification of the reporter

-

Name of person to be contacted:     

-

Address:      

-

Telephone number:      

Administrative and sponsor information Date of report by the sponsor:      /     /      Origin of the effect/event:

a) biomedical investigation : b) scientific literature (provide a copy):

c) spontaneous notifications : d) other health/registry authority:

Date on which the sponsor first became aware of the adverse event:

     /     /     

Country in which the event occurred:      

Sponsor name:      

Sponsor address:

     

Person delegated by the sponsor to submit the report - Name of the person :     

-

Address:      

-

Telephone number:      

-

Fax number:      

Case ID number assigned by the sponsor:      

Attach a copy of the Serious Adverse Event (SAE) report form filled out by the investigator.

Attach a copy of the hospital report if available

Date:      /     /      Sponsor signature:      

Name:       Title :      

ANSM - version 2 - july 2013 3/3

Références

Documents relatifs

Agence nationale de sécurité du médicament et des produits de santé (ANSM) Direction médicale des dispositifs médicaux, des cosmétiques et des dispositifs de diagnostic in

1121-1 du code de la santé publique portant sur un dispositif médical ou un dispositif médical de diagnostic in vitro. Déclaration de vigilance : informations

Clinical investigation involving a medical device or an in vitro diagnostic

N° d'autorisation commissionnaire en douane habilité à déclarer les stupéfiants (autorisation délivrée par l'ANSM) :      . Adresse

Après application du produit et procédé à tester, signal dans l’effluent ou la solution, avec ou sans signal pour le support : élimination de la protéine prion Oui NON. Pour

Si l’on rapporte le nombre de décès par MSO au nombre de patients traités, on observe que l’incidence des décès par méthadone est toujours bien supérieure à celle de

ANSM - Agence nationale de sécurité du médicament et des produits de santé Formulaire 5 Recherche biomédicale portant sur un dispositif médical ou un.. dispositif médical

ANSM - Agence nationale de sécurité du médicament et des produits de santé Formulaire 6 Recherche biomédicale portant sur un dispositif médical ou dispositif.. médical de